Who Uses It and Why
• Oncologists: Ordered by more than 50% of U.S. oncologists, doctors use the test to evaluate post-surgical residual disease, help decide whether a patient needs adjuvant chemotherapy, monitor treatment response (such as during immunotherapy), and catch cancer relapses earlier than traditional scans.
• Cancer Patients: Patients diagnosed with solid tumors (such as colorectal, breast, lung, bladder, ovarian, melanoma, or skin cancers) have the test built from their unique tumor tissue sample, followed by routine serial blood draws during and after treatment.
Covered Cancers & Validation:
The test is covered by Medicare for specific indications—including colorectal, breast, muscle-invasive bladder, non-small cell lung, and ovarian/fallopian/peritoneal cancers, as well as general solid tumor monitoring during immune checkpoint inhibitor therapy.(Natera)
One of the biggest hurdles for Cytodyn, would be testing training & awareness. If that high of a % # of US oncologist are already using Natera, then wow, for Leronlimabs future & significant leverage for Cytodyn in "strategic partnership", discussions with any pharma company.
...
• Oncologists: Ordered by more than 50% of U.S. oncologists, doctors use the test to evaluate post-surgical residual disease, help decide whether a patient needs adjuvant chemotherapy, monitor treatment response (such as during immunotherapy), and catch cancer relapses earlier than traditional scans.
• Cancer Patients: Patients diagnosed with solid tumors (such as colorectal, breast, lung, bladder, ovarian, melanoma, or skin cancers) have the test built from their unique tumor tissue sample, followed by routine serial blood draws during and after treatment.
Covered Cancers & Validation:
The test is covered by Medicare for specific indications—including colorectal, breast, muscle-invasive bladder, non-small cell lung, and ovarian/fallopian/peritoneal cancers, as well as general solid tumor monitoring during immune checkpoint inhibitor therapy.(Natera)
One of the biggest hurdles for Cytodyn, would be testing training & awareness. If that high of a % # of US oncologist are already using Natera, then wow, for Leronlimabs future & significant leverage for Cytodyn in "strategic partnership", discussions with any pharma company.
...
1
